Fotodinámiás kezelés idoskori maculadegenerá cióban

András Seres, András Papp, I. Süveges

Research output: Article

Abstract

Introduction: Exsudative form of age-related macular degeneration is the leading cause of legal blindness in elderly. Purpose: The purpose of this study is to report 3.5 years experience with photodynamic therapy in this disorder. Patients and methods: Patient files of all patients underwent photodynamic therapy with verteporfin in Department of Ophthalmology, Semmelweis University, Budapest in a 3.5 years period were reviewed. Changes in visual acuity were considered as main outcome variable compared to natural history data. Results: From April, 2000 to September 2003, 302 patients were treated using photodynamic therapy with verteporfin for exsudative form of age-related macular degeneration. The mean change of visual acuity were 2.6 and 2,7 lines at 12 and 24 months, respectively, while according to the natural history data 4.2 and 4.5 could have been expected. After 2 years, 83% of the patients had visual acuity better than or equal to 20/200 (this is the level of legal blindness), while only 33% was expected according to natural history data. Visual acuity of 20/80 or better (practical ambulatory vision) was found in 39% of the treated eyes (12% in natural history data). There was no severe adverse event. Conclusions: Photodynamic therapy was found to reduce the risk of severe visual loss. The authors' results confirm the data from the international trials. To achieve good results, good patient complience and continuous access to the treatment are indispensible.

Original languageHungarian
Pages (from-to)2143-2149
Number of pages7
JournalOrvosi Hetilap
Volume146
Issue number42
Publication statusPublished - 2005

Fingerprint

Photochemotherapy
Macular Degeneration
Natural History
Visual Acuity
Blindness
Ophthalmology

Keywords

  • Age-related macular degeneration
  • Photodynamic therapy
  • Verteporfin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fotodinámiás kezelés idoskori maculadegenerá cióban. / Seres, András; Papp, András; Süveges, I.

In: Orvosi Hetilap, Vol. 146, No. 42, 2005, p. 2143-2149.

Research output: Article

Seres, A, Papp, A & Süveges, I 2005, 'Fotodinámiás kezelés idoskori maculadegenerá cióban', Orvosi Hetilap, vol. 146, no. 42, pp. 2143-2149.
Seres, András ; Papp, András ; Süveges, I. / Fotodinámiás kezelés idoskori maculadegenerá cióban. In: Orvosi Hetilap. 2005 ; Vol. 146, No. 42. pp. 2143-2149.
@article{19006548c59a439b8297e546ddd899b2,
title = "Fotodin{\'a}mi{\'a}s kezel{\'e}s idoskori maculadegener{\'a} ci{\'o}ban",
abstract = "Introduction: Exsudative form of age-related macular degeneration is the leading cause of legal blindness in elderly. Purpose: The purpose of this study is to report 3.5 years experience with photodynamic therapy in this disorder. Patients and methods: Patient files of all patients underwent photodynamic therapy with verteporfin in Department of Ophthalmology, Semmelweis University, Budapest in a 3.5 years period were reviewed. Changes in visual acuity were considered as main outcome variable compared to natural history data. Results: From April, 2000 to September 2003, 302 patients were treated using photodynamic therapy with verteporfin for exsudative form of age-related macular degeneration. The mean change of visual acuity were 2.6 and 2,7 lines at 12 and 24 months, respectively, while according to the natural history data 4.2 and 4.5 could have been expected. After 2 years, 83{\%} of the patients had visual acuity better than or equal to 20/200 (this is the level of legal blindness), while only 33{\%} was expected according to natural history data. Visual acuity of 20/80 or better (practical ambulatory vision) was found in 39{\%} of the treated eyes (12{\%} in natural history data). There was no severe adverse event. Conclusions: Photodynamic therapy was found to reduce the risk of severe visual loss. The authors' results confirm the data from the international trials. To achieve good results, good patient complience and continuous access to the treatment are indispensible.",
keywords = "Age-related macular degeneration, Photodynamic therapy, Verteporfin",
author = "Andr{\'a}s Seres and Andr{\'a}s Papp and I. S{\"u}veges",
year = "2005",
language = "Hungarian",
volume = "146",
pages = "2143--2149",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "42",

}

TY - JOUR

T1 - Fotodinámiás kezelés idoskori maculadegenerá cióban

AU - Seres, András

AU - Papp, András

AU - Süveges, I.

PY - 2005

Y1 - 2005

N2 - Introduction: Exsudative form of age-related macular degeneration is the leading cause of legal blindness in elderly. Purpose: The purpose of this study is to report 3.5 years experience with photodynamic therapy in this disorder. Patients and methods: Patient files of all patients underwent photodynamic therapy with verteporfin in Department of Ophthalmology, Semmelweis University, Budapest in a 3.5 years period were reviewed. Changes in visual acuity were considered as main outcome variable compared to natural history data. Results: From April, 2000 to September 2003, 302 patients were treated using photodynamic therapy with verteporfin for exsudative form of age-related macular degeneration. The mean change of visual acuity were 2.6 and 2,7 lines at 12 and 24 months, respectively, while according to the natural history data 4.2 and 4.5 could have been expected. After 2 years, 83% of the patients had visual acuity better than or equal to 20/200 (this is the level of legal blindness), while only 33% was expected according to natural history data. Visual acuity of 20/80 or better (practical ambulatory vision) was found in 39% of the treated eyes (12% in natural history data). There was no severe adverse event. Conclusions: Photodynamic therapy was found to reduce the risk of severe visual loss. The authors' results confirm the data from the international trials. To achieve good results, good patient complience and continuous access to the treatment are indispensible.

AB - Introduction: Exsudative form of age-related macular degeneration is the leading cause of legal blindness in elderly. Purpose: The purpose of this study is to report 3.5 years experience with photodynamic therapy in this disorder. Patients and methods: Patient files of all patients underwent photodynamic therapy with verteporfin in Department of Ophthalmology, Semmelweis University, Budapest in a 3.5 years period were reviewed. Changes in visual acuity were considered as main outcome variable compared to natural history data. Results: From April, 2000 to September 2003, 302 patients were treated using photodynamic therapy with verteporfin for exsudative form of age-related macular degeneration. The mean change of visual acuity were 2.6 and 2,7 lines at 12 and 24 months, respectively, while according to the natural history data 4.2 and 4.5 could have been expected. After 2 years, 83% of the patients had visual acuity better than or equal to 20/200 (this is the level of legal blindness), while only 33% was expected according to natural history data. Visual acuity of 20/80 or better (practical ambulatory vision) was found in 39% of the treated eyes (12% in natural history data). There was no severe adverse event. Conclusions: Photodynamic therapy was found to reduce the risk of severe visual loss. The authors' results confirm the data from the international trials. To achieve good results, good patient complience and continuous access to the treatment are indispensible.

KW - Age-related macular degeneration

KW - Photodynamic therapy

KW - Verteporfin

UR - http://www.scopus.com/inward/record.url?scp=33644823107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644823107&partnerID=8YFLogxK

M3 - Article

C2 - 16315995

AN - SCOPUS:33644823107

VL - 146

SP - 2143

EP - 2149

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 42

ER -